Adverum Biotechnologies Releases Promising Phase 2 Trial Data

An announcement from Adverum Biotechnologies ( (ADVM) ) is now available.

On December 4, 2025, Adverum Biotechnologies announced two-year follow-up data from its LUNA Phase 2 clinical trial of Ixo-vec, showing a significant reduction in anti-VEGF injection burden for wet AMD patients. The trial results demonstrated a ~90% reduction in injection rates and sustained anatomic control, reinforcing Ixo-vec’s potential to reduce treatment burden and provide durable disease control. The company plans to complete full enrollment of its pivotal Phase 3 ARTEMIS trial by December 5, 2025, exceeding its original target.

The most recent analyst rating on (ADVM) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Adverum Biotechnologies stock, see the ADVM Stock Forecast page.

Spark’s Take on ADVM Stock

According to Spark, TipRanks’ AI Analyst, ADVM is a Neutral.

Adverum Biotechnologies’ overall stock score is primarily impacted by its financial performance, which is currently weak due to persistent losses and cash flow challenges. While technical analysis shows positive momentum, the negative valuation metrics, such as a negative P/E ratio, weigh heavily on the overall score.

To see Spark’s full report on ADVM stock, click here.

More about Adverum Biotechnologies

Adverum Biotechnologies, Inc. operates in the biotechnology industry, focusing on developing gene therapy products. The company’s primary product candidate, Ixoberogene soroparvovec (Ixo-vec), is designed for the treatment of wet age-related macular degeneration (AMD), a significant market within ophthalmology.

Average Trading Volume: 683,290

Technical Sentiment Signal: Sell

Current Market Cap: $91.84M

For an in-depth examination of ADVM stock, go to TipRanks’ Overview page.